Oncotype DX and Ribociclib
The Oncotype DX test is highly effective at identifying the 70% of patients who can safely avoid chemotherapy and the 30% for whom chemotherapy is optimal. A sample of a tumour is sent to the US wher...
Forum Discussion
ribociclib (Kisqali) is on the Australian Pharmaceutical Benefits Scheme (PBS) for the treatment of both advanced/metastatic breast cancer and early-stage breast cancer at high risk of recurrence. The listing for early breast cancer was expanded in July 2025, making it accessible for eligible patients with high-risk HR+/HER2- Stage 2 and 3, node-positive disease. The cost to the patient is significantly reduced through this listing.
For advanced/metastatic breast cancer: Ribociclib is listed for use in combination with a non-steroidal aromatase inhibitor or fulvestrant.
For early breast cancer: As of July 2025, it is listed for high-risk HR+/HER2- Stage 2 and 3, node-positive breast cancer, in combination with an aromatase inhibitor.
Patient cost: A script costs $41.30, or $6.60 for concession card holders.
Benefit: The PBS listing reduces financial barriers and expands treatment options for many Australians with breast cancer.